Publicação

Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)

Ver documento

Detalhes bibliográficos
Resumo:Background: There is little experience in the economic evaluation of pharmacy/primary care collaborative health interventions using interprofessional technology-driven communication under real-world conditions. This study aimed to conduct cost-effectiveness and cost-utility analyses of a collaborative care intervention in hypertension and hyperlipidemia management between pharmacies and primary care versus usual (fragmented) care alongside a trial. Methods: An economic evaluation was conducted alongside a 6-month pragmatic quasi-experimental controlled trial. Data sources included primary care clinical software; pharmacy dispensing software; patient telephone surveys; and published literature. The target population was adult patients on hypertension and/or lipid-lowering medication. The perspective was societal. We collected patient-level data on resource use to estimate trial costs. Effect outcomes included blood pressure (BP) and quality-adjusted life years (QALYs). Bootstrapping was used to estimate uncertainty around the incremental cost-effectiveness and cost-utility ratios. Cost-effectiveness planes and acceptability curves were estimated. Results: The intervention was not shown to have reasonable levels of cost-effectiveness or cost-utility when compared to usual care as denoted by the levels of uncertainty expressed in wide confidence intervals. The probability of the intervention being cost-effective is 28% at the threshold of €20,000 per QALY gained and 57% at the threshold of €500 per mmHg systolic BP decrease. Conclusion: Considering the limitations of the trial which affected effectiveness and economic outcomes, our results are not generalizable for community pharmacy and primary care in Portugal. This research offers, however, valuable lessons on methods and strategies that can be used in future economic evaluations of collaborative public health interventions with the potential for reimbursement.
Autores principais:Costa, Suzete
Outros Autores:Guerreiro, José; Teixeira, Inês; Helling, Dennis K.; Pereira, João; Mateus, Céu
Assunto:Community pharmacy Cost-effectiveness Cost-utility Economic Hyperlipidemia Hypertension Primary care Real-world
Ano:2022
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Universidade de Lisboa
Idioma:inglês
Origem:Repositório da Universidade de Lisboa
_version_ 1866810899747045376
author Costa, Suzete
author2 Guerreiro, José
Teixeira, Inês
Helling, Dennis K.
Pereira, João
Mateus, Céu
author2_role author
author
author
author
author
author_facet Costa, Suzete
Guerreiro, José
Teixeira, Inês
Helling, Dennis K.
Pereira, João
Mateus, Céu
author_role author
contributor_name_str_mv Repositório Científico de Acesso Aberto da ULisboa
country_str PT
creators_json_txt [{\"Person.name\":\"Costa, Suzete\",\"Person.identifier.orcid\":\"0000-0002-4521-5473\"},{\"Person.name\":\"Guerreiro, José\"},{\"Person.name\":\"Teixeira, Inês\"},{\"Person.name\":\"Helling, Dennis K.\"},{\"Person.name\":\"Pereira, João\"},{\"Person.name\":\"Mateus, Céu\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Repositório Científico de Acesso Aberto da ULisboa
datacite.creators.creator.creatorName.fl_str_mv Costa, Suzete
Guerreiro, José
Teixeira, Inês
Helling, Dennis K.
Pereira, João
Mateus, Céu
datacite.date.Accepted.fl_str_mv 2022-01-01T00:00:00Z
datacite.date.available.fl_str_mv 2022-10-13T11:27:33Z
datacite.date.embargoed.fl_str_mv 2022-10-13T11:27:33Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Community pharmacy
Cost-effectiveness
Cost-utility
Economic
Hyperlipidemia
Hypertension
Primary care
Real-world
datacite.titles.title.fl_str_mv Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
dc.contributor.none.fl_str_mv Repositório Científico de Acesso Aberto da ULisboa
dc.creator.none.fl_str_mv Costa, Suzete
Guerreiro, José
Teixeira, Inês
Helling, Dennis K.
Pereira, João
Mateus, Céu
dc.date.Accepted.fl_str_mv 2022-01-01T00:00:00Z
dc.date.available.fl_str_mv 2022-10-13T11:27:33Z
dc.date.embargoed.fl_str_mv 2022-10-13T11:27:33Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv http://hdl.handle.net/10451/54762
dc.language.none.fl_str_mv eng
dc.publisher.none.fl_str_mv Frontiers
dc.rights.cclincense.fl_str_mv http://creativecommons.org/licenses/by/4.0/
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.subject.none.fl_str_mv Community pharmacy
Cost-effectiveness
Cost-utility
Economic
Hyperlipidemia
Hypertension
Primary care
Real-world
dc.title.fl_str_mv Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
description Background: There is little experience in the economic evaluation of pharmacy/primary care collaborative health interventions using interprofessional technology-driven communication under real-world conditions. This study aimed to conduct cost-effectiveness and cost-utility analyses of a collaborative care intervention in hypertension and hyperlipidemia management between pharmacies and primary care versus usual (fragmented) care alongside a trial. Methods: An economic evaluation was conducted alongside a 6-month pragmatic quasi-experimental controlled trial. Data sources included primary care clinical software; pharmacy dispensing software; patient telephone surveys; and published literature. The target population was adult patients on hypertension and/or lipid-lowering medication. The perspective was societal. We collected patient-level data on resource use to estimate trial costs. Effect outcomes included blood pressure (BP) and quality-adjusted life years (QALYs). Bootstrapping was used to estimate uncertainty around the incremental cost-effectiveness and cost-utility ratios. Cost-effectiveness planes and acceptability curves were estimated. Results: The intervention was not shown to have reasonable levels of cost-effectiveness or cost-utility when compared to usual care as denoted by the levels of uncertainty expressed in wide confidence intervals. The probability of the intervention being cost-effective is 28% at the threshold of €20,000 per QALY gained and 57% at the threshold of €500 per mmHg systolic BP decrease. Conclusion: Considering the limitations of the trial which affected effectiveness and economic outcomes, our results are not generalizable for community pharmacy and primary care in Portugal. This research offers, however, valuable lessons on methods and strategies that can be used in future economic evaluations of collaborative public health interventions with the potential for reimbursement.
dirty 0
eu_rights_str_mv openAccess
format article
fulltext.url.fl_str_mv https://repositorio.ulisboa.pt/bitstreams/7f514b9e-4543-48a2-9a39-d33b678502a8/download
id ul_a92e2d7a0c1ec1ffef35ccfe858e8dde
identifier.url.fl_str_mv http://hdl.handle.net/10451/54762
instacron_str ul
institution Universidade de Lisboa
instname_str Universidade de Lisboa
language eng
network_acronym_str ul
network_name_str Repositório da Universidade de Lisboa
oai_identifier_str oai:repositorio.ulisboa.pt:10451/54762
organization_str_mv urn:organizationAcronym:ul
person_str_mv Costa, Suzete
Costa, Suzete
http://orcid.org/0000-0002-4521-5473
0000-0002-4521-5473
Guerreiro, José
Teixeira, Inês
Helling, Dennis K.
Pereira, João
Mateus, Céu
publishDate 2022
publisher.none.fl_str_mv Frontiers
reponame_str Repositório da Universidade de Lisboa
repository_id_str urn:repositoryAcronym:ul
service_str_mv urn:repositoryAcronym:ul
spelling engFrontierspt_PTBackground: There is little experience in the economic evaluation of pharmacy/primary care collaborative health interventions using interprofessional technology-driven communication under real-world conditions. This study aimed to conduct cost-effectiveness and cost-utility analyses of a collaborative care intervention in hypertension and hyperlipidemia management between pharmacies and primary care versus usual (fragmented) care alongside a trial. Methods: An economic evaluation was conducted alongside a 6-month pragmatic quasi-experimental controlled trial. Data sources included primary care clinical software; pharmacy dispensing software; patient telephone surveys; and published literature. The target population was adult patients on hypertension and/or lipid-lowering medication. The perspective was societal. We collected patient-level data on resource use to estimate trial costs. Effect outcomes included blood pressure (BP) and quality-adjusted life years (QALYs). Bootstrapping was used to estimate uncertainty around the incremental cost-effectiveness and cost-utility ratios. Cost-effectiveness planes and acceptability curves were estimated. Results: The intervention was not shown to have reasonable levels of cost-effectiveness or cost-utility when compared to usual care as denoted by the levels of uncertainty expressed in wide confidence intervals. The probability of the intervention being cost-effective is 28% at the threshold of €20,000 per QALY gained and 57% at the threshold of €500 per mmHg systolic BP decrease. Conclusion: Considering the limitations of the trial which affected effectiveness and economic outcomes, our results are not generalizable for community pharmacy and primary care in Portugal. This research offers, however, valuable lessons on methods and strategies that can be used in future economic evaluations of collaborative public health interventions with the potential for reimbursement.application/pdfpt_PTCost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)PersonalCosta, SuzeteDSpacehttp://dspace.org/items/44ded07d-217a-4c1d-bd60-934fa4097aacDSpacehttp://dspace.org/items/44ded07d-217a-4c1d-bd60-934fa4097aacCostaSuzeteORCIDhttp://orcid.org0000-0002-4521-5473Guerreiro, JoséTeixeira, InêsHelling, Dennis K.Pereira, JoãoMateus, CéuHostingInstitutionOrganizationalRepositório Científico de Acesso Aberto da ULisboae-mailmailto:repositorio@reitoria.ulisboa.ptrepositorio@reitoria.ulisboa.ptDOIIsPartOf10.3389/fphar.2022.9032702022-10-13T11:27:33Z20222022-01-01T00:00:00ZHandlehttp://hdl.handle.net/10451/54762http://purl.org/coar/access_right/c_abf2open accessCommunity pharmacyCost-effectivenessCost-utilityEconomicHyperlipidemiaHypertensionPrimary careReal-world2525006 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal article2022http://creativecommons.org/licenses/by/4.0/http://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://repositorio.ulisboa.pt/bitstreams/7f514b9e-4543-48a2-9a39-d33b678502a8/downloadFrontiers in Pharmacology13
spellingShingle Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
Costa, Suzete
Community pharmacy
Cost-effectiveness
Cost-utility
Economic
Hyperlipidemia
Hypertension
Primary care
Real-world
status SINGLETON
subject.fl_str_mv Community pharmacy
Cost-effectiveness
Cost-utility
Economic
Hyperlipidemia
Hypertension
Primary care
Real-world
title Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
title_full Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
title_fullStr Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
title_full_unstemmed Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
title_short Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
title_sort Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in portugal alongside a trial compared with usual care (USFarmácia®)
topic Community pharmacy
Cost-effectiveness
Cost-utility
Economic
Hyperlipidemia
Hypertension
Primary care
Real-world
topic_facet Community pharmacy
Cost-effectiveness
Cost-utility
Economic
Hyperlipidemia
Hypertension
Primary care
Real-world
url http://hdl.handle.net/10451/54762
visible 1